These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Incidence and therapy of cytomegalovirus disease after liver transplantation. Wiens M; Lefèbre B; Blumhardt G; Schmidt CA; Lohmann R; Neuhaus P Transplant Proc; 1993 Apr; 25(2):1985-6. PubMed ID: 8385829 [No Abstract] [Full Text] [Related]
24. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Duncan SR; Grgurich WF; Iacono AT; Burckart GJ; Yousem SA; Paradis IL; Williams PA; Johnson BA; Griffith BP Am J Respir Crit Care Med; 1994 Jul; 150(1):146-52. PubMed ID: 8025741 [TBL] [Abstract][Full Text] [Related]
25. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group. Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972 [No Abstract] [Full Text] [Related]
26. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC; Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359 [TBL] [Abstract][Full Text] [Related]
28. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. Boivin G; Erice A; Crane DD; Dunn DL; Balfour HH J Infect Dis; 1993 Aug; 168(2):332-5. PubMed ID: 8393055 [TBL] [Abstract][Full Text] [Related]
29. Comparison of ganciclovir- and immune globulin-containing regimens in preventing cytomegalovirus infection in patients with renal transplants. Walton T; Sankari B; Wyner L Am J Health Syst Pharm; 1999 Sep; 56(18):1831-4. PubMed ID: 10511232 [TBL] [Abstract][Full Text] [Related]
30. [Prevention of cytomegalovirus infection and disease in the transplantation patient]. Cisneros JM; Pachón J Enferm Infecc Microbiol Clin; 1993 Jan; 11(1):40-4. PubMed ID: 8384888 [No Abstract] [Full Text] [Related]
31. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients. McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799 [TBL] [Abstract][Full Text] [Related]
35. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890 [TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden. Johanssson I; Mårtensson G; Andersson R Scand J Infect Dis; 2010; 42(2):129-36. PubMed ID: 20082575 [TBL] [Abstract][Full Text] [Related]
37. Prophylaxis of CMV infection after BMT. Zaia JA; Schmidt GM Bone Marrow Transplant; 1992; 10 Suppl 1():139-43. PubMed ID: 1325854 [No Abstract] [Full Text] [Related]
38. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem. Kuypers DR; Vanrenterghem YF Nephrol Dial Transplant; 1999 Oct; 14(10):2304-8. PubMed ID: 10528649 [No Abstract] [Full Text] [Related]